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Abstract
Background: In hemodialysis (HD) patients cardiovascular events represent the predominant cause 
of mortality. Since platelet and monocyte activity markers play an important role in cardiovascular 
mortality, this study assessed the influence of HD on these markers. 
Methods: Forty one HD patients (25 male, 16 female) were included. Blood samples were obtained 
before and after a single HD session at baseline and again after an elapsed period of 114 ± 21 days (91–
–175 days) on maintenance hemodialysis. Surface expression of CD40L and CD62P on platelets, tissue 
factor binding on monocytes and platelet-monocyte aggregates were measured by flow cytometry. Plasma 
levels of monocyte chemotactic protein-1 (MCP-1), interleukin-6 (IL-6), tumor necrosis factor alpha  
(TNFa) and soluble CD40L were analyzed by enzyme linked immunosorbent assay.
Results: Tissue factor on monocytes was significantly increased after a single HD session at baseline 
(p = 0.041), whereas platelet-monocyte aggregates, the expression of CD40L and CD62P on platelets 
did not change significantly. After a mean of 114 ± 21 days of HD therapy, tissue factor on monocytes 
(p < 0.0001), platelet-monocytes aggregates (p < 0.0001), plasma levels of MCP-1 (p = 0.012) and 
TNFa (p = 0.046) were significantly decreased compared to baseline values. In contrast, platelet surface 
expression of CD40L and CD62P as well as plasma levels of sCD40L and IL-6 were not attenuated 
significantly. There was no significant correlation detected between the markers examined and the cu-
mulative time on hemodialysis.
Conclusions: Platelet and monocyte activity markers assessed in this study do not appear to be signifi-
cantly increased by HD therapy. Therefore, these markers probably cannot be accountable for increased 
cardiovascular mortality in chronic HD patients. (Cardiol J 2018; 25, 5: 595–600)
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Introduction
Despite renal replacement therapy using he-
modialysis (HD), end-stage renal disease (ESRD) is 
associated with increased cardiovascular morbidity 
and mortality, mainly due to cardiovascular events. 
HD therapy aims to reduce renal morbidity and 
overall mortality in ESRD patients. However, as-
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sociations between mortality and the dialysis dose 
applied have been studied with negative results in 
patients on maintenance dialysis [1, 2]. 
Prevalent complications in patients with chron-
ic kidney diseases are alterations in hemostasis, 
which correlate with the progressive loss of renal 
function to ESRD. Both, bleeding diathesis and 
thromboembolic events have been identified in 
ESRD patients and increased circulating inflam-
matory proteins predict a worse prognosis [3, 4]. 
Plasma levels of coagulation factors are normal to 
elevated in these patients. Therefore, the occur-
rence of hemorrhagic events is mainly a result of 
platelet dysfunction [5]. Efficient hemostasis re-
quires the secretion of several adhesive substances 
by platelets, as well as adhesion and aggregation 
of platelets at the site of vascular injury [6]. In 
ESRD impaired platelet adhesiveness as well as 
abnormal interactions between platelets and the 
endothelium yields altered platelet function [7]. 
Despite appropriate anticoagulation during HD, 
uremic toxins and the increased platelet activation 
may contribute to altered platelet function in ESRD 
patients [8]. In the development of atherosclero-
sis interaction between activated platelets and 
endothelial cells plays an crucial pathophysiologic 
role [9]. In detail, these interactions mediate the 
development of atherosclerosis by an increased 
expression of vascular cell adhesion molecules and 
their ligands. These include P-selectin, an a-gran-
ule protein that mediates platelet rolling, leukocyte 
adhesion and coagulation, tissue factor expression 
on monocytes, platelet-monocyte-aggregates, and 
CD40L, a member of the tumor necrosis factor 
alpha (TNFa) family of proteins [10]. CD40L and 
CD62P are expressed on activated platelets and are 
directly involved in the interaction of platelets with 
monocytes and endothelial cells [11].
Cardiovascular events related to thrombosis 
account for an excessive mortality in chronic HD 
patients [12]. In this respect the CD40 receptor 
and its ligand (CD40L) on activated platelets are 
of particular interest. They are known to modulate 
both inflammation and thrombosis, which promote 
the development of clinical atherosclerosis [13]. 
Tissue factor expression on monocytes is impor-
tant in extrinsic coagulation and elevated in HD 
patients compared to healthy controls [14]. 
Whether ESRD itself or chronic HD therapy 
over and above is responsible for these alterations 
in hemostasis and the consecutively elevated 
cardiovascular mortality is still unclear. Thus, in 
order to investigate possible procoagulatory effects 
of HD on established markers of atherosclerosis, 
the present study assessed the short and long-term 
effects of HD on platelet and monocyte activity 
markers of atherosclerosis. 
Methods
Study population and protocol
For this prospective longitudinal study 41 
HD patients (25 male, 16 female) were included 
consecutively. Patient characteristics and baseline 
medication are displayed in Tables 1 and 2. 
In order to investigate short- and long-term 
effects of HD on markers of atherosclerosis, tissue 
factor binding on monocytes, platelet-monocytes-
aggregates, and platelet surface expression of 
CD40L and CD62P were measured at the beginning 
and the end of a single HD session (time A) and 
again after a mean of 114 ± 21 days (91–175 days) 
(time B, at the beginning of the HD session).
Plasma concentrations of TNFa, interleukin-6 
(IL-6), monocyte chemotactic protein-1 (MCP-1) 
and soluble CD40L were determined at baseline 
(time A) and again after a mean of 114 ± 21 days 
(91–175 days) (time B).
The investigation conforms to the principles 
outlined in the Declaration of Helsinki. The study 
was approved by the local ethics committee and all 
Table 2. Medication in use.
Medication Hemodialysis  
patients (n = 41)
ASA 5 (12%)
Anti-coagulants 9 (22%)
Beta-blocker 22 (54%)
CSE-inhibitor 4 (10%)
ACEI/AT(1) antagonist 20 (49%)
ACEI — angiotensin converting enzyme inhibitor; ASA — acetyl-
salicylic acid
Table 1. Study population.
Hemodialysis  
patients (n = 41)
Age [years] 61.83 ± 15.42
Male 25 (61%)
Hyperlipoproteinemia 6 (15%)
Coronary artery disease 12 (29%)
Peripheral arterial disease 8 (20%)
Diabetes mellitus 15 (37%)
Hypertension 35 (85%)
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patients gave informed consent to the use of their 
medical record for research purposes.
Patients were hemodialyzed with hollow-fiber 
polysulfone membrane dialysators with a 1.2 m2 
surface area (n = 40) (Polysulfon UF 4.0; Haemoflow 
F5, Fresenius, Germany) or with a cellulose triacetate 
dialysator (n = 1) (CT 150 G, Baxter, Germany) with 
bicarbonate-containing solutions for 13.2 h (range 
9–20 h) weekly. All the patients were advised to com-
ply with a chronic renal failure diet consisting of 35 
kcal/kg, including 1.2–1.4 g/kg of protein, 1000–1500 
mg of calcium, 700 mg of phosphorus and 250 mg of 
magnesium, vitamins and recombinant human eryth-
ropoietin. The Kt/V was assessed once for each HD 
patient at the beginning of the study at timepoint A. 
The mean Kt/V was 1.53 ± 0.28. Patients were on 
HD for 47.78 months (range 2–157 months) at the 
time of entry to the study. All patients were routinely 
dialysed 3 days per week.
Flow cytometric analysis
Blood samples of heparinized blood (15 IE 
heparin per ml blood) (Sarstedt AG & Co/Nuembre-
cht, Germany) were obtained. To avoid procedural 
aggregation and activation of platelets, the blood 
samples were shaken over the time. All whole 
blood samples were subsequently investigated on 
activation of monocytes and platelets as well as 
platelet binding on monocytes. 
Flow cytometric analysis of platelets was 
performed by gating in forward and side scatter. 
Platelets were gated back for determination of 
the expression of CD40L and CD62P. Platelet-
-monocyte aggregates were measured by CD41 
(GPIIb/IIIa receptor) surface expression on plate-
lets adherent to monocytes. 
For the analysis of platelets, 100 μL of each 
whole blood sample was stained for 30 min at room 
temperature with 10 μL aliquots of mouse anti-hu-
man CD62P-PE antibodies (CLB-Thromb/6) (Coul-
ter Immunotech/Krefeld, Germany) and mouse 
anti-human CD40L-FITC antibodies (P2) (Calbio-
chem/Merck KGaA, Darmstadt, Germany). For the 
analysis of monocytes, 100 μL of each whole blood 
sample were stained for 30 min at room tempera-
ture with 10 μL aliquots of PE-conjugated murine 
antibody against CD41 (Coulter Immunotech/
Krefeld, Germany) and murine FITC-conjugated 
antibody against tissue factor (American Diagnos-
tica/Pfungstadt, Germany). To identify monocytes, 
the probes were additionally stained with mouse 
anti-human CD14-ECD (RM052) (Coulter Immu-
notech/Krefeld, Germany). Isotype matched mouse 
anti-human IgG1 PE/FITC antibodies (Beckman 
Coulter/Marseille, France) were used as a control. 
After incubation, erythrocytes were lysed with 
500 μL Optilyse C (Coulter Immunotech/Krefeld, 
Germany). After 15 min, cells were resuspended 
in 500 μL phosphate buffered saline and were then 
ready for flow cytometric analysis. For measure-
ment of CD40L and CD62P on platelets, a gating 
for forward and sideward scatter was performed. 
For measurement of CD41 on platelets adherent 
to monocytes to determine platelet-monocyte-
aggregates and for assessment of membrane bound 
tissue factor a gating for the monocyte surface 
antigen CD14 and sideward scatter was performed. 
All flow cytometric analysis was performed on 
an EPICS XL-MCL analyzer (Beckman Coulter, 
Krefeld, Germany) equipped with an argon laser 
tuned at 488 nm. Compensation of the four-channel 
fluorescence was precisely adjusted using Cyto-
CompTM reagents and Cyto-TrolTM control cells 
(Coulter Immunotech/Krefeld, Germany).
Enzyme linked immunosorbent assay  
(ELISA)
Plasma concentrations of TNFa (Human 
TNFa/TNFSF1A Immunoassay R&D Systems, 
Inc., Wiesbaden, Germany), IL-6 (Human IL-6 
Immunoassay R&D Systems, Inc., Wiesbaden, 
Germany), MCP-1 (Human MCP-1/CCL2 Immuno-
assay R&D Systems, Inc., Wiesbaden, Germany), 
soluble CD40L (Human soluble CD40 Ligand 
Immunoassay R&D Systems, Inc., Wiesbaden, 
Germany) were determined by sandwich-type 
immunoassay according to the manufacturer’s 
instructions. All concentration analysis was per-
formed on an ELISA-Reader — Lab Systems 
Multiskan RC (Lab systems, Finland). Genesis 
Lite Software, ELISA Multiskan RC was used for 
data acquisition and evaluation.
Statistical analysis
Numerical data were expressed as mean ± 
standard deviation (SD). A Mann-Whitney test 
was applied as a nonparametric test. Categorical 
variables were analyzed using a c2 test and t-test. 
Values are expressed as mean values ± SD. A two-
tailed probability < 0.05 was considered significant. 
All calculations were performed using GraphPad 
InStat version 3.01 (GraphPad Software, San Diego, 
California, USA) and SPSS Statistics version 17 
(SPSS-Software GmbH, Munich, Germany).
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Results
Influence of a single hemodialysis session 
on markers of atherosclerosis
Tissue factor binding on monocytes signifi-
cantly increased during the dialysis session (before 
dialysis: 1.32 ± 0.29; after dialysis: 1.43 ± 0.4; 
p = 0.041, Fig. 1). Regarding the amount of plate-
let-monocyte aggregates (before dialysis: 19.3 ± 
± 10.44; after dialysis: 21.08 ± 15.23; p = NS) 
and platelet surface expression of CD40L (before 
dialysis: 5.25 ± 1.68; after dialysis: 5.07 ± 1.14; 
p = NS) and CD62P (before dialysis: 1.91 ± 0.93; 
after dialysis: 1.92 ± 1.29; p = NS), there was no 
significant difference between the values before 
and after the dialysis session (time A).
Long-term effect of hemodialysis  
on markers of atherosclerosis
Tissue factor binding on monocytes (time A: 
1.32 ± 0.29; time B: 0.99 ± 0.22; p < 0.0001; Fig. 2) 
and platelet-monocytes aggregates (time A: 19.3 ± 
± 10.44; time B: 10.53 ± 4.16; p < 0.0001; Fig. 3) 
were significantly decreased between time A and B. 
No significant change was observed in respect 
of platelet surface expression of CD40L (time A: 
5.25 ± 1.68; time B: 5.34 ± 1.16; p = NS) and 
CD62P (time A: 1.91 ± 0.93; time B: 1.81 ± 0.66; 
p = NS) between time A and time B.
Long-term effect of hemodialysis  
on chemokines
Plasma levels of TNFa significantly decreased 
over time (time A: 9.25 ± 11.13 pg/mL; time B: 
4.87 ± 2.44 pg/mL; p = 0.046; Fig. 4), as well as 
plasma levels of MCP-1 (time A: 327.84 ± 157.86 
pg/mL; time B: 288.89 ± 157.87 pg/mL; p = 0.012; 
Fig. 5). Plasma levels of IL-6 (time A: 5.12 ± 3.61 
pg/mL; time B: 5.57 ± 3.84 pg/mL; p = NS) and 
sCD40L (time A: 459.9 ± 722.85 pg/mL; time B: 
234.53 ± 324.6 pg/mL; p = NS) did not change 
significantly over time.
Correlation between dialysis duration and 
markers of atherosclerosis and chemokines
No significant correlation was found between 
the time on dialysis and tissue factor on monocytes 
(r = –0.026; NS), platelet-monocytes aggregates 
(r = 0.042; NS), CD40L (r = –0.156; NS) or CD62P 
(r = –0.231; NS).
Also, there was no correlation between 
the time on dialysis and plasma levels of TNFa 
(r = –0.047; NS), IL-6 (r = 0.066; NS), MCP-1 
(r = 0.008; NS) or sCD40L (r = –0.002; NS).
Figure 1. Tissue factor binding on monocytes before 
and after hemodialysis (HD); MFI — mean fluorescence 
intensity.
Figure 2. Tissue factor binding on monocytes at time A 
and time B; MFI — mean fluoroscence intensity.
Figure 3. Platelet-monocytes aggregates at time A and 
time B; MFI — mean fluorescence intensity.
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Discussion
Patients with ESRD undergo renal replace-
ment therapy to avoid fatal complications of uremic 
toxins, elevated potassium levels and overhydra-
tion. Unfortunately, ESRD is accompanied by 
increased atherosclerotic and thrombembolic 
morbidity and mortality. Both uremic toxins and the 
increase of platelet activation irrespective of appro-
priate anticoagulation during HD may contribute 
to altered platelet function in ESRD patients [8].
To examine possible short- and long-term 
effects of the HD itself, a comparison of the ex-
pression of platelet and monocyte activity markers 
and the tissue factor system was done before and 
after a single HD session and after approximately 
4 months of intermittent maintenance HD therapy. 
During a single dialysis session, a significant in-
crease was revealed in tissue factor on monocytes. 
In contrast, tissue factor on monocytes was sig-
nificantly decreased in the second analysis about 
4 months later and showed no overall correlation 
with the time on dialysis. This might reflect that 
the activation of tissue factor during the dialysis 
session is fluctuating and does not persist or ac-
cumulate over time.
Tissue factor on monocytes is an important 
pro-atherogenic marker in these patients since 
cardiovascular events are closely linked to the 
tissue factor system [15]. Yorioka et al. [14] de-
scribed higher levels of tissue factor on monocytes 
in HD patients in comparison to healthy controls. 
Al-Saady et al. [16] showed a hypercoagulable 
state in patients with chronic renal failure as 
a contributing factor for the increased cardiovascu-
lar and cerebrovascular event rate. Consistent with 
with the presentresults, Kappelmayer et al. [17] 
described an increase of tissue factor on monocytes 
during extracorporal circulation.
Kobayashi et al. [18] demonstrated an as-
sociation between platelet-monocyte aggregates 
and surrogate parameters of atherosclerosis like 
brachial-ankle pulse wave velocity and intima 
media thickness. This argues for a worse effect of 
platelet-monocyte aggregates in HD patients but it 
cannot explain why we found a significant decrease 
after approximately 4 months of HD. Gawaz et al. 
[19] demonstrated that various dialysis membranes 
do not influence the formation of platelet-monocyte 
aggregates.
In contrast to the present findings, Naumnik 
et al. [20] showed stable MCP-1 levels before and 
after a HD session, but they did not follow the 
MCP-1 levels over a longer time period as was 
done herein. No significant change was observed 
of MCP-1 levels after a mean HD period of ap-
proximately 4 months. 
Schwabe et al. [21] demonstrated elevated 
levels of sCD40L in patients with chronic renal dis-
ease in comparison to healthy probands, but Rusu 
et al. [22] did not reveal an influence of sCD40L on 
survival or cardiovascular events in HD patients 
in a 108 month follow-up.
Surprisingly, no significant increase was ob-
served in all tested atherosclerotic markers in 
a second measurement approximately 4 months 
later. On the contrary, for tissue factor on mono-
cytes, platelet-monocytes aggregates, plasma-level 
of TNFa and MCP-1 found a significant decrease 
over the time period. This might be due to the fact 
that the initial measurement was not performed 
at the beginning of the need of renal replacement 
therapy during the first dialysis and that therefore 
Figure 5. Plasma levels of monocyte chemotactic pro-
tein-1 (MCP-1; pg/mL) at time A and time B.
Figure 4. Plasma levels of tumor necrosis factor alpha 
(TNFa, pg/mL) at time A and time B.
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the examined levels might have been high already 
at the initial measurement. This is underlined by 
the fact that HD patients had a higher CD62P ex-
pression on platelets, a significantly higher amount 
of platelet-monocyte aggregates, significantly more 
tissue factor binding on monocytes and significantly 
higher levels of TNFa compared to peritoneal 
dialysis patients [23].
Conclusions 
Platelet and monocyte activity markers as-
sessed in this study do not appear to be significantly 
increased by HD therapy. Therefore, these markers 
might not be accountable for increased cardiovas-
cular mortality in chronic HD patients. 
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